|
99 Companies |
|
136 Products |
|
136 Products |
|
121 Mechanisms of Action |
|
5 Trials |
|
1112 News |
|
| «12...567891011121314151617» |
- Trial completion: Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Jul 10, 2013
P=N/A, N=116, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed
- | New P2 trial: Mesalazine Effects in Sporadic Colorectal Adenoma Patients (clinicaltrials.gov) - Jul 8, 2013
P2, N=68, Recruiting, Sponsor: UMC Utrecht
- Enrollment open: Mesalazine Effects in Sporadic Colorectal Adenoma Patients (clinicaltrials.gov) - Jul 8, 2013
P2, N=68, Recruiting, Sponsor: UMC Utrecht
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || escitalopram / Generic mfg.
New P3 trial, Head-to-Head: Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial (clinicaltrials.gov) - Jul 8, 2013
P3, N=240, Recruiting, Sponsor: University of Sao Paulo
- || esomeprazole / Generic mfg.
Enrollment closed: Nexium Capsules RE Maintenance Specific Clinical Experience Investigation (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=647, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | propranolol / Generic mfg.
New P4 trial: PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES? (clinicaltrials.gov) - Jul 7, 2013
P4, N=100, Completed, Sponsor: Federal University of S
- propranolol / Generic mfg.
Trial completion: PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES? (clinicaltrials.gov) - Jul 7, 2013
P4, N=100, Completed, Sponsor: Federal University of S
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- Enrollment open: PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA) (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=20, Recruiting, Sponsor: dr. M.P. van den Tol MD PhD
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Prevent Return of Stroke Study (clinicaltrials.gov) - Jun 27, 2013
P=N/A, N=600, Completed, Sponsor: Mount Sinai School of Medicine
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial initiation date, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment (clinicaltrials.gov) - Jun 27, 2013
P1, N=39, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: Nov 2008 --> Apr 2009
- Enrollment change: CAT-Denmark: Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia (clinicaltrials.gov) - Jun 26, 2013
P=N/A, N=65, Completed, Sponsor: University of Southern Denmark
Initiation date: Nov 2008 --> Apr 2009 N=164 --> 65
- Trial completion: CAT-Denmark: Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia (clinicaltrials.gov) - Jun 26, 2013
P=N/A, N=65, Completed, Sponsor: University of Southern Denmark
N=164 --> 65 Active, not recruiting --> Completed
- | cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
New P1 trial, Surgery: Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery (clinicaltrials.gov) - Jun 25, 2013
P1, N=13, Recruiting, Sponsor: Mayo Clinic
- || Enrollment closed: EURO KLEAR: A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid Lesions Treated Adjunctive to Surgical Excision (clinicaltrials.gov) - Jun 19, 2013
P=N/A, N=51, Active, not recruiting, Sponsor: Halscion, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer (clinicaltrials.gov) - Jun 17, 2013
P2, N=100, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- Ilaris (canakinumab) / Novartis
Enrollment open: Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF (clinicaltrials.gov) - Jun 16, 2013
P2, N=100, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: Low-Dose Naltrexone for Depression Relapse and Recurrence (clinicaltrials.gov) - Jun 9, 2013
P2, N=36, Recruiting, Sponsor: Massachusetts General Hospital
- New P1 trial, Metastases: Dose Escalating Study for Amphinex-based PCI of Bleomycin. (clinicaltrials.gov) - Jun 5, 2013
P1, N=9, Recruiting, Sponsor: PCI Biotech AS
- Avastin (bevacizumab) / Roche
Enrollment closed: Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy (clinicaltrials.gov) - Jun 3, 2013
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | olanzapine / Generic mfg.
New P4 trial: OCTLPODEPWBD: Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder (clinicaltrials.gov) - May 27, 2013
P4, N=60, Completed, Sponsor: Tri-Service General Hospital
- Enrollment closed: Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion (clinicaltrials.gov) - May 27, 2013
P4, N=200, Active, not recruiting, Sponsor: Melbourne Health
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial termination: Net-Pac;NetPac: Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer (clinicaltrials.gov) - May 23, 2013
P3, N=5, Terminated, Sponsor: CHIR-Net
Recruiting --> Active, not recruiting Not yet recruiting --> Terminated; lack of recruitment
- Enrollment change: Net-Pac;NetPac: Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer (clinicaltrials.gov) - May 23, 2013
P3, N=5, Terminated, Sponsor: CHIR-Net
Not yet recruiting --> Terminated; lack of recruitment N=120 --> 5
- ||||||| Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
Trial completion, Surgery, Metastases: Monoclonal Antibody Therapy (Rencarex (clinicaltrials.gov) - May 20, 2013
P3, N=864, Completed, Sponsor: Wilex
N=120 --> 5 Active, not recruiting --> Completed
- cisplatin / Generic mfg.
New P2 trial: S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study (clinicaltrials.gov) - May 14, 2013
P2, N=48, Recruiting, Sponsor: Fudan University
- Trial termination: Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study (clinicaltrials.gov) - May 12, 2013
P=N/A, N=6, Terminated, Sponsor: Cantonal Hospital of St. Gallen
Active, not recruiting --> Completed Suspended --> Terminated; poor patient accrual
- Enrollment change: Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study (clinicaltrials.gov) - May 12, 2013
P=N/A, N=6, Terminated, Sponsor: Cantonal Hospital of St. Gallen
Suspended --> Terminated; poor patient accrual N=27 --> 6
- Trial completion: Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas (clinicaltrials.gov) - May 6, 2013
P=N/A, N=12, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
N=27 --> 6 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer (clinicaltrials.gov) - May 2, 2013
P1/2, N=17, Terminated, Sponsor: Boneca Corporation
Active, not recruiting --> Completed Recruiting --> Terminated; The neutron facility closed down for financial reasons.
- | Leukine (sargramostim) / Partner Therap
Enrollment change: COG-AOST0221: Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma (clinicaltrials.gov) - Apr 29, 2013
P2, N=49, Completed, Sponsor: Children's Oncology Group
Recruiting --> Terminated; The neutron facility closed down for financial reasons. N=40 --> 49
- ||| Trial completion: Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer (clinicaltrials.gov) - Apr 29, 2013
P1, N=60, Completed, Sponsor: Novartis Pharmaceuticals
N=40 --> 49 Active, not recruiting --> Completed
- ||| goserelin acetate / Generic mfg.
Trial completion: PROTECT-Z: PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients (clinicaltrials.gov) - Apr 28, 2013
P=N/A, N=1376, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial, Surgery: Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery (clinicaltrials.gov) - Apr 25, 2013
P2, N=60, Completed, Sponsor: Meshalkin Research Institute of Pathology of Circulation
- || Enrollment change: PROMIS: PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score (clinicaltrials.gov) - Apr 17, 2013
P=N/A, N=820, Recruiting, Sponsor: Agendia
Active, not recruiting --> Completed N=300 --> 820
- Trial completion: The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 17, 2013
P4, N=145, Completed, Sponsor: Seoul National University Hospital
N=300 --> 820 Active, not recruiting --> Completed
- Enrollment open: FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) - Apr 15, 2013
P2, N=25, Recruiting, Sponsor: David M. Schuster, MD
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- pegylated liposomal doxorubicin / Generic mfg.
Trial termination: Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix (clinicaltrials.gov) - Apr 9, 2013
P2, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Recruiting Completed --> Terminated
- cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial termination: Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix (clinicaltrials.gov) - Apr 9, 2013
P2, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Completed --> Terminated Completed --> Terminated
- gemcitabine / Generic mfg.
Trial termination: Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix (clinicaltrials.gov) - Apr 9, 2013
P2, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Completed --> Terminated Completed --> Terminated
- Enrollment change: Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy (clinicaltrials.gov) - Apr 7, 2013
P4, N=184, Completed, Sponsor: Centre for Addiction and Mental Health
Completed --> Terminated N=150 --> 184
- Trial completion: Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy (clinicaltrials.gov) - Apr 7, 2013
P4, N=184, Completed, Sponsor: Centre for Addiction and Mental Health
N=150 --> 184 Active, not recruiting --> Completed
- ||||| Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
New P2 trial: Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder (clinicaltrials.gov) - Apr 4, 2013
P2, N=104, Completed, Sponsor: Bial - Portela C S.A.
- ARC 100 / Cortice Biosci
Trial withdrawal, Metastases: Open-Label Study of TPI 287 for Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 3, 2013
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- ARC 100 / Cortice Biosci
Enrollment change, Metastases: Open-Label Study of TPI 287 for Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 3, 2013
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=82 --> 0
- | Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Trial termination: EMBARC-RF: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 26, 2013
P3, N=84, Terminated, Sponsor: Bioniche Life Sciences Inc.
N=82 --> 0 Active, not recruiting --> Terminated; Lack of Recruitment
- | Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Enrollment change: EMBARC-RF: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 26, 2013
P3, N=84, Terminated, Sponsor: Bioniche Life Sciences Inc.
Active, not recruiting --> Terminated; Lack of Recruitment N=450 --> 84
- Trial initiation date: ABSNOME: The Effect of Sutures Versus Mesh in Umbilical Hernia Repair (clinicaltrials.gov) - Mar 25, 2013
P=N/A, N=1313, Completed, Sponsor: Hvidovre University Hospital
N=450 --> 84 Initiation date: Aug 2012 --> Dec 2012
- ARC 100 / Cortice Biosci
Trial initiation date, Metastases: Open-Label Study of TPI 287 for Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 20, 2013
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Initiation date: Aug 2012 --> Dec 2012 Initiation date: Dec 2012 --> Sep 2013
- Enrollment closed: Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy (clinicaltrials.gov) - Mar 10, 2013
P=N/A, N=750, Active, not recruiting, Sponsor: Seoul National University Hospital
Initiation date: Dec 2012 --> Sep 2013 Recruiting --> Active, not recruiting
- New P2 trial: FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) - Mar 7, 2013
P2, N=25, Recruiting, Sponsor: David M. Schuster, MD